Sulfamides and their use as endothelin receptor antagonists

Details Sulfamides and their use as endothelin receptor antagonists Sulfamides and their use as endothelin receptor antagonists

2007-10-23

2007-10-23

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S255050, C514S269000, C544S123000, C544S296000, C544S319000

Reexamination Certificate

active

11400697

ABSTRACT:
The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

REFERENCES:
patent: 4233294 (1980-11-01), Maurer et al.
patent: 7094781 (2006-08-01), Bolli et al.
patent: 0 526 708 (1993-02-01), None
patent: 0 633 259 (1995-01-01), None
patent: 0 657 548 (1995-06-01), None
patent: 0 743 307 (1996-11-01), None
patent: 0 882 719 (1998-12-01), None
patent: 0 959 072 (1999-11-01), None
patent: WO 96/19459 (1996-06-01), None
patent: WO 96/16963 (1996-12-01), None
patent: WO 00/42035 (2000-07-01), None
patent: WO 01/17976 (2001-03-01), None
patent: WO 01/46156 (2001-06-01), None
patent: WO 01/81335 (2001-11-01), None
patent: WO 01/81338 (2001-11-01), None
Neidhart, W., et el., Discovery of R048-5695: A Potent Mixed Endothelin Receptor Antagonist Optimized from Bosentan, Bioorganic & Medical Chemistry Letters,. 7(17):2223-2228, 1997.
Gohring, W. et al., Development of a Process to Prepare 2-Cyanopyrimidine on commercial Scale, Chimia, 50 Nov. 1996.
Nugent, A., et al, Pyrimidine Thioethers: A Novel Class of HIV' Reverse Transcriptase Inhibitors with Activiity Against BHAP-Resistant HIV, J. Med. Chem., 41: 3793-3803, 1998.
March, Jerry, Advanced Organic Chemistry, Fourth Ed p. 499 end references cited therein, 1992.
Kohara, Y., et al., Synthesis and Angiotensin II Receptor Antagonistic Activities at Benzimldazote Derivatives Bearing Acidic Heterocycles as Novel Tetrazole Bioisosteres, J. Mad. Chem., 39: 5228-5235, 1996.
Graf. R., Chem. Bar., 92:509-513, 1959.
Weiss. G., et al., Liebigs Ann. Chem., 729:40-51, 1969.
Kloek, J., et al., An Improved Synthesis of Sulfamoyl Chlorides, J. Org. Chem., 41 (25):4028-4029, 1976.
Dickinson. R,. et al. Thromboxane Modulating Agents. 3. 1H-Imidazol-1-ylalkyl-and 3-Pyridinylalkyl-Substituted 3-[2-[Arylsulfonyl)amino]ethyl]benzenepropanoic Acid Derivatives as Duel Thromboxane Synlhase Inhibitor/Thromboxane Receptor Antagonists, J. Med. Chem., 40:3442-3452 1997.
Cohen, E., et al., Sulfamoyl Chlohde, Sutfamides and Sulfimide, J. Am. Chem.Soc., 84:1994-2002, 1962.
Olson. A., et al., Orally Active Isoxazoline Glycoprotein IIb/IIIa Antagonists with Extended Duration of Action, J. Med. Chem., 42:1178-1192.1999.
Crosby, D., et al., n-Buty 5-Chloro-2-pyrimidoxyacetate-A Plant Growth Regulator Analog. J. Org. Chem., 25:1916-1919, Nov. 1960.
Morgan, Ed., Synthesis of p-Alkylphenylacetic Acids, Tetrahedron, 23:1735-1738, 1967.
Tozer, M., et al., 4-Chlorobenzyl Sulfonamide and Sulfamide Derivatives of Histamine Homologues: The Design of Potent Histamine H3 Receptor Antagonists Bioorganic & Medicinal Chemistry Letters 9:3103-3108, 1999.
Dewynter, et al., Tetrahedron, 49(1):65-76, 1993.
Bennett. J. Claude, et al., Textbook at Medicine, vol. 1, 20th Edition 1004-1010, 1996.
Rubanyi, G.M.. et al. Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology and Pathophysiology, Pharm. Reviews, 46(3), 1994.
Arai, et al., Cloning and expression of a cDNA encoding an endothelin Recetor Nature, 348:730-732, 1990.
Breu. V. et al., In vitro characterization at R0 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors, FEBS 13244, 334(2):210-214, Nov. 1993.
Neidhart, W., et al, The Discovery of Nonpeptide Endothelin Receptor Antagonists. Progression towards Bosentan, Chemia, 50:519-524, Nov. 1996.
McMillen, M., el al., Endothelins: Polyfunctional Cytokines. J. Amer. College of Surgeons, 180:621-640, 1995.
Ogawa. V. et al., Molecular Cloning of a Non-Isopeptide-Selective Human Endothehin Receptor, Biochem. Biophy. Research Comm., 178(1 ):248-255 Jul. 1991.
Ohlstein, E., et el., Endothelin-I Modulates Vascular Smooth Muscle Structure and Vasomotion: Implications in Cardiovascular Pathology, Drug Development Research, 29:108-128, 1993.
Sakural, et al., Cloning of a cDNA encoding a non-isopeptide-selective subtype at the endothelin receptor, Nature. 348:732-735, Dec. 1990.
Sumner, M., et al., Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction, Br. J. Pharmacol., 107:858-860, 1992.
Yanag1sawa, M., et al., A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, 332:411-415, Mar. 1988.

Affiliated with

Also associated with

Rating

Sulfamides and their use as endothelin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfamides and their use as endothelin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamides and their use as endothelin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854483